Literature DB >> 27453107

[Disease burden of famale breast cancer in China].

L Wang1, Y Zhang1, J F Shi1, M Dai2.   

Abstract

OBJECTIVE: To analyze the data on burden of female breast cancer in China.
METHODS: The data from Chinese Cancer Registry Annual Report 2012, three national death cause surveys in China, Disease Surveillance Points system(DSP), China Health Statistics Yearbook, GLOBOCAN 2012, Cancer Incidence in Five Continents(CI5), WHO Mortality Database and Global Burden of Disease(GBD)2013 were used to extract the incidence, mortality and disability-adjusted life years(DALY)of female breast cancer and analyze related trends in China.
RESULTS: The data from three national death cause surveys showed that the crude mortality of breast cancer doubled from year 1973-1975 to year 2004-2005, the increase was higher in urban area(127.4%)than in rural area(75.2%). WHO Mortality Database showed that average annual percentage change(AAPC)of breast cancer crude mortality increased by 3.1%(P<0.05)from 1987 to 2000, and China Health Statistics Yearbook showed that the AAPC in urban females increased by 2.7% from 2002 to 2013(P<0.05), whereas the AAPC in rural females showed no significant change(P>0.05). It was estimated by GLOBOCAN 2012 that in 2012 the age-standardized incidence and age-standardized mortality of breast cancer in China was 22.1 per 100 000 and 5.4 per 100 000, respectively. The age-specific incidence began to increase obviously at age of 40 years and peaked at age 45-59 years(GLOBOCAN 2012). Chinese Cancer Registry Annual Report 2012 showed that breast cancer incidence and mortality were 2-fold and 1.5-fold higher in urban females than in rural females in 2009. It was estimated that the breast cancer case number and death number in females in China would increase to 251 600 and 75 900, respectively, more increose in age group ≥65 years. Only GBD 2013 reported DALY, the DALY caused by breast cancer in China was 1 666.0 thousand in 2013, accounting for 12.7% of global DALY, and increased by 56.7% from 1990(1 062.6 thousand), the peak age-specific DALY rate was at 50 to 59 years, and national average ratio of years lived with disability(YLD)was 8.7%(ranging from 8.1% to 9.0% at provincial level).
CONCLUSIONS: Burden of disease caused by female breast cancer is becoming increasingly severe in China, especially in urban areas. It is necessary to strengthen the population-based prevention and control programs and further studies may focus on DALY.

Entities:  

Mesh:

Year:  2016        PMID: 27453107     DOI: 10.3760/cma.j.issn.0254-6450.2016.07.013

Source DB:  PubMed          Journal:  Zhonghua Liu Xing Bing Xue Za Zhi        ISSN: 0254-6450


  11 in total

1.  Cost-effectiveness Analysis of Trastuzumab Emtansine as Second-line Therapy for HER2-Positive Breast Cancer in China.

Authors:  Huahua Zhang; Yandong Zhang; Chaonan Huang; Jiangfeng Wang
Journal:  Clin Drug Investig       Date:  2021-04-20       Impact factor: 2.859

2.  [Digital breast tomosynthesis in diagnosis of dense breast lesions].

Authors:  A'qiao Xu; Hongqin He; Qiujun Shi; Zhiqing Li; Shengjian Zhang
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2019-04-25

3.  The associations of genetic polymorphisms in CYP1A2 and CYP3A4 with clinical outcomes of breast cancer patients in northern China.

Authors:  Xianan Bai; Jingjing Xie; Shanshan Sun; Xianyu Zhang; Yongdong Jiang; Da Pang
Journal:  Oncotarget       Date:  2017-06-13

4.  Awareness of Breast Cancer among Female Care Givers in Tertiary Cancer Hospital, China

Authors:  Negalign Getahun Dinegde; Li Xuying
Journal:  Asian Pac J Cancer Prev       Date:  2017-07-27

5.  Economic Evaluation of Letrozole for Early Breast Cancer in a Health Resource-Limited Setting.

Authors:  Ming Ye; Jingsong Lu; Fan Yang; Bin Wu
Journal:  Biomed Res Int       Date:  2018-08-02       Impact factor: 3.411

6.  TMED3 promotes cell proliferation and motility in breast cancer and is negatively modulated by miR-188-3p.

Authors:  Jing Pei; Jing Zhang; Xiaowei Yang; Zhengsheng Wu; Chenyun Sun; Zhaorui Wang; Benzhong Wang
Journal:  Cancer Cell Int       Date:  2019-03-29       Impact factor: 5.722

7.  Mapping function from FACT-B to EQ-5D-5 L using multiple modelling approaches: data from breast cancer patients in China.

Authors:  Qing Yang; Xue Xin Yu; Wei Zhang; Hui Li
Journal:  Health Qual Life Outcomes       Date:  2019-10-15       Impact factor: 3.186

8.  Comparisons of Treatment for HER2-Positive Breast Cancer between Chinese and International Practice: A Nationwide Multicenter Epidemiological Study from China.

Authors:  Yi-Qun Han; Zong-Bi Yi; Pei Yu; Wen-Na Wang; Qu-Chang Ouyang; Min Yan; Xiao-Jia Wang; Xi-Chun Hu; Ze-Fei Jiang; Tao Huang; Zhong-Sheng Tong; Shu-Sen Wang; Yong-Mei Yin; Hui Li; Run-Xiang Yang; Hua-Wei Yang; Yue-E Teng; Tao Sun; Li Cai; Hong-Yuan Li; Xue-Nong Ouyang; Jian-Jun He; Xin-Lan Liu; Shun-E Yang; You-Lin Qiao; Jin-Hu Fan; Jia-Yu Wang; Bing-He Xu
Journal:  J Oncol       Date:  2021-09-15       Impact factor: 4.375

9.  Financial toxicity in female patients with breast cancer: a national cross-sectional study in China.

Authors:  Meicen Liu; Linlin Hu; Xueyan Han; Man Cao; Jing Sun; Yuanli Liu
Journal:  Support Care Cancer       Date:  2022-07-11       Impact factor: 3.359

10.  Reproductive Risk Factors Associated with Breast Cancer Molecular Subtypes among Young Women in Northern China.

Authors:  Jian Ming Wang; Jun Wang; Hong Guang Zhao; Tong Tong Liu; Fei Yang Wang
Journal:  Biomed Res Int       Date:  2020-04-06       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.